Gut microbiota-based translational biomarkers to prevent metabolic syndrome via nutritional modulation

FEMS Microbiology Ecology

Volumn 87, Issue 2, 2014, Pages 303-314

  Xiao, Shuiming ^a   Zhao, Liping ^a,b  

^a Shanghai Jiao Tong University   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Biomarkers; Gut microbiota; Insulin resistance; Metabolic syndrome; Trajectory analysis

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTERIUM; BIOMARKER; CARDIOVASCULAR DISEASE; CHEMICAL BINDING; ETIOLOGY; HOMEOSTASIS; METABOLISM; MORBIDITY; MORTALITY; PLASMA; TRAJECTORY;

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARRIER PROTEIN; INSULIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN;

ANIMAL; ARTICLE; BLOOD; DIET THERAPY; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INTESTINE; INTESTINE FLORA; METABOLIC SYNDROME X; METABOLISM; MICROBIOLOGY; MICROFLORA; TRAJECTORY ANALYSIS;

BIOMARKERS; GUT MICROBIOTA; INSULIN RESISTANCE; METABOLIC SYNDROME; TRAJECTORY ANALYSIS;

ACUTE-PHASE PROTEINS; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARRIER PROTEINS; GASTROINTESTINAL TRACT; HUMANS; INSULIN; INSULIN RESISTANCE; INTESTINES; MEMBRANE GLYCOPROTEINS; METABOLIC SYNDROME X; MICROBIOTA;

EID: 84893478225     PISSN: 01686496     EISSN: 15746941     Source Type: Journal    
DOI: 10.1111/1574-6941.12250     Document Type: Article

References (143)

1. Ajslev T, Andersen C, Gamborg M, Sørensen T & Jess T (2011) Childhood overweight after establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and early administration of antibiotics. Int J Obes (Lond) 35: 522-529.
2. Alberti KGMM, Zimmet P & Shaw J (2005) The metabolic syndrome-a new worldwide definition. Lancet 366: 1059-1062.
3. Alberti KGMM, Zimmet P & Shaw J (2006) Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23: 469-480.
4. Alvarez JA, Higgins PB, Oster RA, Fernandez JR, Darnell BE & Gower BA (2009) Fasting and postprandial markers of inflammation in lean and overweight children. Am J Clin Nutr 89: 1138-1144.
5. An HM, Park SY, Lee DK, Kim JR, Cha MK, Lee SW, Lim HT, Kim KJ & Ha NJ (2011) Antiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats. Lipids Health Dis 10: 116.
6. Ärnlöv J, Ingelsson E, Sundström J & Lind L (2010) Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 121: 230-236.
7. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF & Gordon JI (2004) The gut microbiota as an environmental factor that regulates fat storage. P Natl Acad Sci USA 101: 15718-15723.
8. Bays H, Evans JL, Maki KC, Evans M, Maquet V, Cooper R & Anderson JW (2012) Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized controlled trial. Eur J Clin Nutr 67: 2-7.
9. Bo S, Musso G, Gambino R, Villois P, Gentile L, Durazzo M, Cavallo-Perin P & Cassader M (2012) Prognostic implications for insulin-sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort. Am J Clin Nutr 96: 962-969.
10. Brignardello J, Morales P, Diaz E, Romero J, Brunser O & Gotteland M (2010) Pilot study: alterations of intestinal microbiota in obese humans are not associated with colonic inflammation or disturbances of barrier function. Aliment Pharmacol Ther 32: 1307-1314.
11. Bulló M, Casas-Agustench P, Amigó-Correig P, Aranceta J & Salas-Salvadó J (2007) Inflammation, obesity and comorbidities: the role of diet. Public Health Nutr 10: 1164-1172.
12. Caesar R, Fåk F & Bäckhed F (2010) Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med 268: 320-328.
13. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J & Shoelson SE (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 11: 183-190.
14. Cani PD & Delzenne NM (2009) Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol 9: 737-743.
15. Cani PD & Delzenne NM (2011) The gut microbiome as therapeutic target. Pharmacol Ther 130: 202-212.
16. Cani PD, Amar J, Iglesias MA et al. (2007a) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761-1772.
17. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR & Delzenne NM (2007b) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50: 2374-2383.
18. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM & Burcelin R (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 1470-1481.
19. Cani PD, Lecourt E, Dewulf EM, Sohet FM, Pachikian BD, Naslain D, De Backer F, Neyrinck AM & Delzenne NM (2009) Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 90: 1236-1243.
20. Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, del Vecchio Blanco C & Loguercio C (2011) Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis 43: 431-438.
21. Chen JJ, Wang R, Li X-F & Wang R-L (2011) Bifidobacterium longum supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I gene expression. Exp Biol Med (Maywood) 236: 823-831.
22. Coats SR, Berezow AB, To TT, Jain S, Bainbridge BW, Banani KP & Darveau RP (2011) The lipid A phosphate position determines differential host Toll-like receptor 4 responses to phylogenetically related symbiotic and pathogenic bacteria. Infect Immun 79: 203-210.
23. Cox LM & Blaser MJ (2013) Pathways in microbe-induced obesity. Cell Metab 17: 883-894.
24. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL & Kumar S (2007) Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292: E740-E747.
25. Delzenne NM & Cani PD (2010) Nutritional modulation of gut microbiota in the context of obesity and insulin resistance: potential interest of prebiotics. Int Dairy J 20: 277-280.
26. Delzenne NM & Cani PD (2011) Gut microbiota and the pathogenesis of insulin resistance. Curr Diab Rep 11: 154-159.
27. Delzenne NM, Neyrinck AM & Cani PD (2011) Modulation of the gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome. Microb Cell Fact 10: S10.
28. Derrien M, Vaughan EE, Plugge CM & de Vos WM (2004) Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol 54: 1469-1476.
29. Després JP, Poirier P, Bergeron J, Tremblay A, Lemieux I & Alméras N (2008) From individual risk factors and the metabolic syndrome to global cardiometabolic risk. Eur Heart J Suppl 10: B24-B33.
30. Devaraj S, Rosenson RS & Jialal I (2004) Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 33: 431-453.
31. Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR & Thissen J-P (2013) Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62: 1112-1121.
32. Dietrich M & Jialal I (2005) The effect of weight loss on a stable biomarker of inflammation, C-reactive protein. Nutr Rev 63: 22-28.
33. Eckel RH, Grundy SM & Zimmet PZ (2005) The metabolic syndrome. Lancet 365: 1415-1428.
34. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y & Morii H (1999) Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 22: 818-822.
35. Erridge C, Bennett-Guerrero E & Poxton IR (2002) Structure and function of lipopolysaccharides. Microbes Infect 4: 837-851.
36. Erridge C, Attina T, Spickett CM & Webb DJ (2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86: 1286-1292.
37. Everard A & Cani PD (2013) Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 27: 73-83.
38. Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM, Possemiers S, Van Holle A, François P & de Vos WM (2011) Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60: 2775-2786.
39. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG & Delzenne NM (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. P Natl Acad Sci USA 110: 9066-9071.
40. Fåk F & Bäckhed F (2012) Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/- mice. PLoS One 7: e46837.
41. Fayh APT, Lopes AL, da Silva AMV, Reischak-Oliveira Á & Friedman R (2013) Effects of 5% weight loss through diet or diet plus exercise on cardiovascular parameters of obese: a randomized clinical trial. Eur J Nutr 52: 1443-1450.
42. Fei N & Zhao L (2013) An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J 7: 880-884.
43. Franco OH, Massaro JM, Civil J, Cobain MR, O'Malley B & D'Agostino RB (2009) Trajectories of entering the metabolic syndrome. Circulation 120: 1943-1950.
44. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H & Koenig W (2000) Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care 23: 1835-1839.
45. Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, Sikaris K, Ebeling PR & Daly RM (2012) Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). J Clin Endocrinol Metab 97: 1953-1961.
46. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT & Ye J (2009) Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58: 1509-1517.
47. Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, Fernandez-Real JM & Dandona P (2009) Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal. Diabetes Care 32: 2281-2287.
48. Gregor M & Hotamisligil G (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29: 415-445.
49. Grundy SM (2012) Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 59: 635-643.
50. Grundy SM, Cleeman JI, Daniels SR et al. (2006) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 21: 1-6.
51. Gubern C, Lopez-Bermejo A, Biarnes J, Vendrell J, Ricart W & Fernandez-Real JM (2006) Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. Diabetes 55: 216-224.
52. Guerra RA, Casafont F, Crespo J, Cayón A, Mayorga M, Estebanez A, Fernadez-Escalante J & Pons-Romero F (2007) Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 17: 1374-1380.
53. Haffner SM (2006) The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 97: 3-11.
54. Hajer GR, Van Der Graaf Y, Olijhoek JK, Verhaar MC & Visseren FLJ (2007) Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome. Heart 93: 216-220.
55. Hakansson A & Molin G (2011) Gut microbiota and inflammation. Nutrients 3: 637-682.
56. Hansen CHF, Krych L, Nielsen DS, Vogensen FK, Hansen LH, Sørensen SJ, Buschard K & Hansen A (2012) Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia 55: 2285-2294.
57. Heilbronn LK, Noakes M & Clifton PM (2001) Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 21: 968-970.
58. Hiura M, Kikuchi T, Nagasaki K & Uchiyama M (2003) Elevation of serum C-reactive protein levels is associated with obesity in boys. Hypertens Res 26: 541-546.
59. Hotamisligil G, Shargill N & Spiegelman B (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91.
60. Imayama I, Ulrich CM, Alfano CM, Wang C, Xiao L, Wener MH, Campbell KL, Duggan C, Foster-Schubert KE & Kong A (2012) Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Res 72: 2314-2326.
61. Kalathil S, Napier C, Pattman S, Wark G, Abouglila K & James R (2013) Variable characteristics with insulin assays. Pract Diab 30: 118-120.
62. Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka T, Matsuhisa M, Kajimoto Y, Ichijo H, Yamasaki Y & Hori M (2004) Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 10: 1128-1132.
63. Karlsson CL, Önnerfält J, Xu J, Molin G, Ahrné S & Thorngren-Jerneck K (2012) The microbiota of the gut in preschool children with normal and excessive body weight. Obesity 20: 2257-2261.
64. Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, Nielsen J & Bäckhed F (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498: 99-103.
65. Kassi E, Pervanidou P, Kaltsas G & Chrousos G (2011) Metabolic syndrome: definitions and controversies. BMC Med 9: 48.
66. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, Araki-Sasaki R, Hori Y, Yano Y & Adachi Y (2001) Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 24: 362-365.
67. Kelly CJ, Colgan SP & Frank DN (2012) Of microbes and meals: the health consequences of dietary endotoxemia. Nutr Clin Pract 27: 215-225.
68. Kim E (2010) Insulin resistance at the crossroads of metabolic syndrome: systemic analysis using microarrays. Biotechnol J 5: 919-929.
69. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, Terasawa K, Kashihara D, Hirano K & Tani T (2013) The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 4: 1829.
70. Kovatcheva-Datchary P & Arora T (2013) Nutrition, the gut microbiome and the metabolic syndrome. Best Pract Res Clin Gastroenterol 27: 59-72.
71. Lajunen T, Vikatmaa P, Bloigu A, Ikonen T, Lepäntalo M, Pussinen PJ, Saikku P & Leinonen M (2008) Chlamydial LPS and high-sensitivity CRP levels in serum are associated with an elevated body mass index in patients with cardiovascular disease. Innate Immun 14: 375-382.
72. Lann D & LeRoith D (2007) Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am 91: 1063-1077.
73. Lee JG, Lee S, Kim YJ, Jin HK, Cho BM, Kim YJ, Jeong DW, Park HJ & Kim JE (2009) Multiple biomarkers and their relative contributions to identifying metabolic syndrome. Clin Chim Acta 408: 50-55.
74. Lepper P, Schumann C, Triantafilou K, Rasche F, Schuster T, Frank H, Schneider E, Triantafilou M & von Eynatten M (2007) Association of lipopolysaccharide-binding protein and coronary artery disease in men. J Am Coll Cardiol 50: 25-31.
75. Ley RE (2010) Obesity and the human microbiome. Curr Opin Gastroenterol 26: 5-11.
76. Ley RE, Turnbaugh PJ, Klein S & Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444: 1022-1023.
77. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874.
78. Lindberg AA, Weintraub A, Zähringer U & Rietschel ET (1990) Structure-activity relationships in lipopolysaccharides of Bacteroides fragilis. Rev Infect Dis 12: S133-S141.
79. Liou AP, Paziuk M, Luevano J-M Jr, Machineni S, Turnbaugh PJ & Kaplan LM (2013) Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 5: 178ra141.
80. Manco M, Putignani L & Bottazzo GF (2010) Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31: 817-844.
81. Mansfield MW, Heywood DM & Grant PJ (1996) Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 94: 2171-2176.
82. Matsuura M (2013) Structural modifications of bacterial lipopolysaccharide that facilitate Gram-negative bacteria evasion of host innate immunity. Front Immunol 4: 109.
83. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D & Turner R (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
84. Meigs JB, Muller DC, Nathan DM, Blake DR & Andres R (2003) The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes 52: 1475-1484.
85. Moller D & Berger J (2003) Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes (Lond) 27: S17-S21.
86. Monteiro R & Azevedo I (2010) Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm 2010: 289645.
87. Monzillo LU & Hamdy O (2003) Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev 61: 397-412.
88. Moreira APB, Texeira TFS, Ferreira AB, do Carmo Gouveia Peluzio M & de Cássia Gonçalves Alfenas R (2012) Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr 108: 801-809.
89. Moreno-Navarrete JM, Ortega F, Serino M et al. (2012) Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) 36: 1442-1449.
90. Morrison DC & Ryan JL (1987) Endotoxins and disease mechanisms. Annu Rev Med 38: 417-432.
91. Musso G, Gambino R & Cassader M (2010) Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care 33: 2277-2284.
92. Musso G, Gambino R & Cassader M (2011) Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med 62: 361-380.
93. Neuschwander-Tetri BA & Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219.
94. Neyrinck A, Van Hée V, Piront N, De Backer F, Toussaint O, Cani P & Delzenne N (2012) Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr Diabetes 2: e28.
95. Nicklas JM, Sacks FM, Smith SR, LeBoff MS, Rood JC, Bray GA & Ridker PM (2013) Effect of dietary composition of weight loss diets on high-sensitivity C-reactive protein: the Randomized POUNDS LOST trial. Obesity 21: 681-689.
96. Novitsky TJ (1998) Limitations of the Limulus amebocyte lysate test in demonstrating circulating lipopolysaccharides. Ann NY Acad Sci 851: 416-421.
97. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jorgensen T & Hildebrandt P (2005) N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 46: 660-666.
98. Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, Sari I, Yazici M & Keleş I (2006) Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens 19: 1055-1062.
99. Parnell JA & Reimer RA (2009) Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr 89: 1751-1759.
100. Pepys MB & Baltz ML (1983) Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34: 141-212.
101. Piéroni L, Bastard JP, Piton A, Khalil L, Hainque B & Jardel C (2003) Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. Diabetes Metab 29: 133-138.
102. Pradhan AD, Manson JE, Rifai N, Buring JE & Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc 286: 327-334.
103. Prasad A & Quyyumi AA (2004) Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 110: 1507-1512.
104. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y & Shen D (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490: 55-60.
105. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595.
106. Rydén L, Standl E, Malgorzata B et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 28: 88-136.
107. Santacruz A, Marcos A, Wärnberg J et al. (2009) Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity 17: 1906-1915.
108. Santacruz A, Collado M, García-Valdés L, Segura M, Martín-Lagos J, Anjos T, Marti-Romero M, Lopez R, Florido J & Campoy C (2010) Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr 104: 83-92.
109. Sanz Y, Santacruz A & Gauffin P (2010) Gut microbiota in obesity and metabolic disorders. Proc Nutr Soc 69: 434-441.
110. Scholze J, Alegria E, Ferri C, Langham S, Stevens W, Jeffries D & Uhl-Hochgraeber K (2010) Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model. BMC Public Health 10: 529.
111. Schröder NWJ & Schumann RR (2005) Non-LPS targets and actions of LPS binding protein (LBP). J Endotoxin Res 11: 237-242.
112. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS & Ulevitch RJ (1990) Structure and function of lipopolysaccharide binding protein. Science 249: 1429-1433.
113. Scott KP, Gratz SW, Sheridan PO, Flint HJ & Duncan SH (2012) The influence of diet on the gut microbiota. Pharmacol Res 69: 52-60.
114. Seino S, Shibasaki T & Minami K (2011) Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest 121: 2118-2125.
115. Servais A, Giral P, Bernard M, Bruckert E, Deray G & Isnard Bagnis C (2008) Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med 121: 426-432.
116. Shen J, Obin MS & Zhao L (2012) The gut microbiota, obesity and insulin resistance. Mol Aspects Med 34: 39-58.
117. Sonnenburg JL, Xu J, Leip DD, Chen CH, Westover BP, Weatherford J, Buhler JD & Gordon JI (2005) Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 307: 1955-1959.
118. Staten MA, Stern MP, Miller WG, Steffes MW & Campbell SE (2010) Insulin assay standardization leading to measures of insulin sensitivity and secretion for practical clinical care. Diabetes Care 33: 205-206.
119. Stern MP, Williams K & Haffner SM (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136: 575-581.
120. Stern MP, Williams K, González-Villalpando C, Hunt KJ & Haffner SM (2004) Does the metabolic-syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 27: 2676-2681.
121. Sun L, Yu Z, Ye X et al. (2010) A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care 33: 1925-1932.
122. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M & Witte DR (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373: 2215-2221.
123. Turnbaugh PJ, Bäckhed F, Fulton L & Gordon JI (2008) Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3: 213-223.
124. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R & Gordon JI (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1: 6ra14.
125. Tzounis X, Rodriguez-Mateos A, Vulevic J, Gibson GR, Kwik-Uribe C & Spencer JP (2011) Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. Am J Clin Nutr 93: 62-72.
126. Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM & Rensen SS (2013) Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity DOI: 10.1002/oby.20466.
127. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE & Gewirtz AT (2010) Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328: 228-231.
128. Vrieze A, Nood EV, Holleman F et al. (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143: 913-916.
129. Vulevic J, Juric A, Tzortzis G & Gibson GR (2013) A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr 143: 324-331.
130. Wellen KE & Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115: 1111-1119.
131. WHO (2005) Preventing Chronic Diseases: A Vital Investment. WHO technical report series: 894, World Health Organization, Geneva.
132. Wild SH & Byrne CD (2006) The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. The Metabolic Syndrome, (Wild SH & Byrne CD, eds), pp. 1-41. John Wiley & Sons, Inc., Chichester, UK.
133. Xiao S, Fei N, Pang X et al. (2013) A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol DOI: 10.1111/1574-6941.12228.
134. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS & Tartaglia LA (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830.
135. Yeni-Komshian H, Carantoni M, Abbasi F & Reaven GM (2000) Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 23: 171-175.
136. Zeyda M & Stulnig TM (2007) Adipose tissue macrophages. Immunol Lett 112: 61-67.
137. Zhang C, Zhang M, Wang S et al. (2010) Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J 4: 232-241.
138. Zhang C, Zhang M, Pang X, Zhao Y, Wang L & Zhao L (2012a) Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. ISME J 6: 1848-1857.
139. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, Li M, Zhang C, Zhang Z & Zhang Y (2012b) Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 7: e42529.
140. Zhang C, Li S, Yang L et al. (2013) Structural modulation of gut microbiota in life-long calorie-restricted mice. Nat Commun 4: 2163.
141. Zhao L (2013) The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol 11: 639-647.
142. Zhao L & Shen J (2010) Whole-body systems approaches for gut microbiota-targeted, preventive healthcare. J Biotechnol 149: 183-190.
143. Zuo H, Shi Z, Yuan B, Dai Y, Wu G & Hussain A (2013) Association between serum leptin concentrations and insulin resistance: a population-based study from China. PLoS One 8: e54615.